ArticleNPJ vaccines2025
To generate functional anti-protease-activated receptor-4 (PAR4), a G protein-coupled receptor, antibodies through PAR4-mRNA-LNP immunization.
Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- mRNA-Encoded Antibodies: An Emerging Paradigm in Antiviral Protection.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
G protein-coupled receptors (GPCRs) are key therapeutic targets for various diseases, such as the thrombin receptor protease-activated receptor 4 (PAR4) involved in thrombotic cardiovascular disorders. However, the structural complexity of native GPCRs hinders recombinant protein production, making peptide-based immunization insufficient for generating high-quality antibodies. Here, we developed a PAR4-mRNA-LNP vaccine to express native PAR4 in vivo, thereby inducing potent and specific anti-PAR4 antibodies. The PAR4-mRNA-LNP formulation showed 93.44% encapsulation efficiency, an average size of 127.5 nm, and a polydispersity index (PDI) of 0.1033. Native 55-kDa PAR4 protein with complete glycosylation was confirmed on the cell surface using western blotting and flow cytometry. Mice immunized with PAR4-mRNA-LNP produced strong anti-PAR4 antibody responses, as detected by cell-based ELISA. Finally, we established hybridoma cell lines and identified five clones that significantly inhibited PAR4-mediated platelet aggregation. These findings suggest that mRNA-LNP technology can be broadly applied to generate functional anti-GPCR antibodies for therapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.